Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay
© Grant et al.; licensee BioMed Central Ltd. 2012
Received: 20 June 2012
Accepted: 7 September 2012
Published: 10 October 2012
Understanding the mechanisms that maintain protective antibody levels after immunisation is important for vaccine design. In this study, we have determined the kinetics of plasma and memory B cells detectable in the blood of cattle immunised with model T-dependent or T-independent antigens. Immunisation with the T-D antigen resulted in an expansion of TNP-specific plasma cells post-TNP primary and booster immunisations, which was associated with increased titres of TNP-specific IgG antibodies. Although no TNP-specific memory B cells were detected in the T-D group following the primary immunisation, we detected an increase in the number of TNP-specific memory B cells post-TNP boost. In contrast, no TNP-specific plasma or memory B cells were detected after primary or secondary immunisation with the T-I antigen. We then investigated if immunisation with a third party antigen (tetanus toxin fragment C, TTC) would result in a bystander stimulation and increase the number of TNP-specific plasma and memory B cells in the T-D and/or T-I group. TTC immunisation in the T-D group resulted in a small increase in the number of TNP-specific plasma cells post-TTC primary immunisation and boost, and in an increase in the number of TNP-specific memory B cells post-TTC boost. This bystander effect was not observed in the animals previously immunised with the T-I antigen. In conclusion, the present study characterised for the first time the B cell response in cattle to immunisation with T-D and T-I antigens and showed that bystander stimulation of an established T-D B cell memory response may occur in cattle.
Antibodies play a vital role in preventing viral infection and offer protection against subsequent re-challenge, providing protective antibody titres are maintained. The maintenance of long-term protective antibodies following primary antigen exposure is provided by a combination of memory B cells and long-lived plasma cells, at least in mice. On the basis of their size, nature and structure, antigens can induce T cell dependent (T-D) or T cell independent (T-I) immune responses. We have previously shown that the B cell ELISPOT assay can be used to detect and enumerate antigen-specific plasma and memory B cells in cattle immunised with ovalbumin, a T-dependent (T-D) antigen. However, there are currently no data available regarding the kinetics of these cells in the blood of cattle immunised with a T-independent (T-I) antigen.
Antigens that induce T-cell help to orchestrate a high affinity class-switched serological response are termed T-D antigens. During a T-D antigenic challenge, a small proportion of activated B cells differentiate into short-lived plasma cells within the T-cell regions of the secondary lymphoid organs and secrete low affinity antibodies for a short period of time. The remaining activated B cells are recruited to the B cell follicles to form germinal centres, where the process of somatic hypermutation occurs (improving the B cell receptor affinity for their cognate antigen by 1 to 2 orders of magnitude)[6, 7]; both long-lived plasma cells and memory B cells are generated and selected. Long-lived plasma cells migrate to specific niches within the bone marrow and spleen, where they secrete high-affinity antibodies for prolonged periods. In contrast, memory B cells continuously circulate without secreting antibodies.
Conversely, T-I antigens are able to initiate a serological response in the absence of T-cell help. There are two types of T-I antigens, type 1 are polyclonal B cell stimulants and type 2 are non-polyclonal stimulants. Type 2 T-I antigens possess highly organised, repeating structures that are able to activate naïve B cells in the absence of CD4+ T cell help, by cross linking multiple B cell receptors (BCRs) on the naïve B cell surface[11, 12]. A second signal is required by the activated B cell to stimulate antibody production, either via TLR stimulation[3, 13] or complement activation and CD21 stimulation. However, whilst B cells can be activated by type 2 T-I antigens, development of long-term memory B cells to these antigens is limited, particularly in children under 2 years of age and in neonatal mice. It has been demonstrated that T-I antigens, such as polysaccharides, can be altered, via conjugation to a protein carrier, producing a T-D response, which results in the induction of sustained immunological memory[15, 16].
Many pathogens contain both T-I and T-D antigens, virus capsids that have a repetitive/non-random structure, such as foot-and-mouth disease virus, FMDV, with antigenic epitopes spaced 5–10 nm apart) tend to preferentially generate a T-I immunological response[1, 16]. Indeed, T cell depletion studies in cattle have shown that FMDV invokes a largely type 2 T-I response to structural proteins.
Upon re-exposure to a specific antigen or upon polyclonal stimulation, memory B cells differentiate into plasma cells and secrete antibodies. Several mechanisms of polyclonal memory B cell stimulation have been previously described in mice and humans, including “bystander stimulation” from activated bystander CD4+ T-cells via cytokines, from microbial products via TLR stimulation (e.g. CpG DNA and LPS), or from other B cell-activating molecules such as BAFF, APRIL and C4bp that are able to drive the differentiation of memory B cells into plasma cells in a T-independent manner. This mechanism of “bystander stimulation”, thought to be an antigen-independent mechanism for the continuous replenishment of the plasma cell pool and thereby maintenance of protective antibody titres, has never been described in cattle.
In the present study, we assessed and compared the kinetics of plasma and memory B cells generated in cattle immunised with either a T-D antigen (the hapten 2,4,6-trinitrophenyl, TNP, conjugated to chicken gamma globulin, TNP-CGG) or type 2 T-I antigen (TNP conjugated to aminoethylcarboxymethyl-FICOLL, TNP-AECM-FICOLL). We also investigated whether a subsequent immunisation with a third party antigen exerted an effect upon the B cell response previously established to either the T-D or type 2 T-I antigen.
Materials and methods
Calves and immunisation protocols
Ten male 8-month-old conventionally reared Holstein-Friesian calves (Bos Taurus, Institute for Animal Health, Compton, UK) were split into two randomly selected groups of five. In the first group, each calf was subcutaneously immunised with 3 mg of the hapten 2,4,6-trinitrophenyl (TNP) conjugated to the T-D antigen chicken gamma globulin (TNP-CGG, Biosearch technologies, Novato, CA, USA) in QuilA adjuvant (Superfos Speciality Chemical a/s, Vedbaek, Denmark). In the second group, each calf was subcutaneously immunised with 3 mg of TNP conjugated to the T-I antigen aminoethylcarboxymethyl-FICOLL (TNP-AECM-FICOLL, Biosearch technologies, Novato, CA, USA) in QuilA adjuvant. All calves were boost-immunised 29-days later with the same immunising antigens, as described above (TNP-CGG in the T-D group and TNP-AECM-FICOLL in the T-I group). At day 134 post-primary immunisation (pi) all calves, from both groups, were subcutaneously immunised with 3 mg of tetanus toxin fragment C (TTC, PX’Therapeutics, Grenoble, France) in incomplete Freund’s adjuvant (IFA, Difco Laboratories, Detroit, MI, USA). Subsequently, all animals were boosted with TTC and IFA at day 197 pi. A group of control animals were given a primary and booster immunisation of adjuvant alone (including IFA). These animals showed no detectable antigen-specific plasma, memory B cells or IgG titres throughout the study. Heparinised peripheral blood and serum samples were taken from all animals at various time points following the immunisations. All experiments were approved by the Institute’s ethical review process and were in accordance with national guidelines on animal use.
Bovine peripheral blood mononuclear cell (PBMC) isolation
Bovine PBMCs were isolated from the heparinised peripheral blood samples using density gradient centrifugation. The blood samples were diluted 1:2 using Dulbecco’s phosphate buffered saline (dPBS, Invitrogen), layered over Histopaque® 1.083 g/mL (Sigma-Aldrich) and centrifuged for 30 min at 1200 × g. The mononuclear cell layer was recovered after centrifugation and remaining red cells were lysed using ammonium chloride lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH7.2). After two further washing steps using dPBS, the PBMCs were enumerated using a Neubauer haemocytometer (Hawksley, Lancing, UK). A fraction of the enumerated fresh PBMCs were diluted to the required concentration and stored at 4°C until required for the detection of plasma cells.
Memory B cell culture
An “ELISPOT medium” was used in all experiments aimed at quantifying plasma and memory B cells and consisted of RPMI 1640 with L-Glutamine and 25 mM Hepes (Invitrogen, Paisley, UK) supplemented with penicillin (100 units/mL), streptomycin (100 μg/mL), 1× non-essential amino acids (Sigma-Aldrich, Gillingham, UK), 1 mM sodium pyruvate and 15% heat-inactivated horse serum (Sigma-Aldrich).At the indicated time-points, some PBMCs were cultured as described below to induce the terminal differentiation of memory B cells into antibody secreting cells (ASC) prior to their detection by ELISPOT assay. Briefly, 2 × 107 bovine PBMCs were cultured for 6 days in 20 mL of ELISPOT media (final PBMC concentration: 1 × 106/mL) supplemented with 5 μg/mL pokeweed mitogen (PWM, Sigma-Aldrich), 10 μg/mL anti-bovine CD40 mAb (ILA158, kindly donated by ILRI, Kenya), 20 ng/mL recombinant human IL-2 (AMS Biotechnology Ltd, Abingdon, UK) and 7.3 units/mL bovine IL-10 (kindly donated by Dr G Entrican, Moredun Research Institute, Midlothian, UK). At the end of the culture period, the 6 day-cultured PBMC were recovered, washed twice in ELISPOT media, enumerated and stored on ice until being used for the detection of induced ASC by ELISPOT assay.
Plasma and memory B cell quantification by ELISPOT
MultiScreen™–HA plates (Millipore, Watford, UK) were coated with either 0.25 μg/mL TNP-Ovalbumin (TNP-Ova), 1/1000 Chicken serum (containing CGG, Sigma-Aldrich) or 10 μg/mL TTC (PX’Therapeutics) in 0.1 M carbonate buffer (pH 9.6) for 2 h at 37°C. Plates were then washed 5 times in PBS and then blocked using 4% dried milk (Marvel, Premier Foods, St Albans, UK) in PBS. Following blocking, the plates were washed 5 times in PBS and stored at 4°C until required.
Fresh or 6 day-cultured PBMCs were suspended at 5 × 106 cells/mL and 1:2 serial dilutions were performed in ELISPOT medium down to 1.5 × 105 cells/mL. 100 μL/well of each suspension (in duplicate) was then incubated on the coated plates overnight at 37°C in a 5% CO2 incubator. Subsequently, the PBMCs were washed from the plates 5 times using PBS containing 0.05% Tween20 (Sigma-Aldrich). 100 μL per well of a 1/1000 dilution of sheep anti-bovine IgG conjugated to horseradish peroxidase (AbD Serotec, Kidlington, UK) was then added to the plates for 3 h at room temperature. Following the incubation step, the plates were again washed 5 times using PBS containing 0.05% Tween20. Detection was performed by the addition of 100 μL/well of 3-amino-9-ethylcarbonate substrate (AEC, Merck, Darmstadt, Germany) and subsequent incubation at room temperature for 1 h. The reaction was stopped by washing the plates with tap water and allowing them to dry overnight at room temperature.
Enumeration of the red coloured spots on the dried ELISPOT plates was performed using the automated AID ELIspot reader (Autoimmun Diagnostika GmbH, Strasbourg, Germany). Each individual “spot” was used as an indicator for an ASC. The ELISPOT results were manually validated for false positives and expressed as ASC number per 106 PBMCs for plasma cells and induced-ASC number per 106 cultured PBMCs for memory B cells (mean of duplicates). During the ELIspot data analysis any well with less than 2 spots was considered to be negative and were treated as having zero ASCs detected (minimum sensitivity: 4 ASCs per 1 × 106 PBMCs). There was very little variance (< 17%) shown between the duplicate observations within each animal.
Enzyme-linked immunoabsorbent assays (ELISA)
96-well plastic plates (BD biosciences, Oxford, UK) were coated for 1 h at room temperature with 100 μL/well of either 20 μg/mL TNP-OVA (Biosearch Technologies) or 10 μg/mL TTC (PX’Therapeutics) in carbonate buffer. Following incubation the plates were washed 5 times in PBS containing 1% Tween20 (Sigma-Aldrich). The plates were then blocked for 1 h using 100 μL/well of PBS containing 1% Tween20 and 4% dried milk (blocking buffer), followed by a washing step, as described above. Serum samples (in duplicate) were serially diluted 1:3 in blocking buffer starting at 1/50 dilution, and 100 μL per well of each diluted serum was added before incubating the plate for 1 h at room temperature. For determination of the plate background optical density (OD) values, some wells were incubated with blocking buffer alone. Following the incubation, the plates were washed and incubated for 1 h at room temperature after addition of 100 μL/well of 1/100,000 dilution of sheep anti-bovine IgG conjugated to horseradish peroxidase (AbD Serotec). Following washing, the plates were incubated for 10 min with 3,3’,5,5’-tetra-methyl benzidine (TMB, Sigma-Aldrich) substrate at room temperature. The reaction was stopped by the addition of 50 μL of 1.2 M H2SO4. The OD values at 450 nm and 690 nm were determined, for each well using a Biotek ELx 808 absorbance plate reader (Biotek, Winooski, VT, USA). The antigen-specific antibody titres were calculated as follows: the log10 values of sample dilutions were plotted against the log10 values of sample OD and a regression analysis was performed on the linear part of the curve allowing the endpoint titre to be calculated using an OD of twice the background. Results were expressed as the mean of duplicate determinations.
Data for the number of antigen-specific IgG ASCs (for plasma and memory B cells) were log + 1 transformed, then analysed using mixed linear models including time (as a factor) and vaccine (TNP-CGG or TNP-AECM-Ficoll), and an interaction between them as fixed effects and between animals as a random effect. Model selection proceeded by stepwise deletion of non-significant (P > 0.05) terms as judged by likelihood ratio tests. Data were considered significant if the calculated P values were < 0.05.
Antibody titre kinetics following primary and booster immunisations with a T-D versus T-I antigen
Plasma cell and memory B cell kinetics following primary and booster immunisations with a T-D versus T-I antigen
Immunisation with TTC induces an increase in TTC-specific plasma and memory B cells
Each of the calves from both the T-D and T-I groups were immunised with a third party antigen (TTC) at day 134 pi and were re-immunised with TTC at day 197 pi.
Immunisation with TTC induces an increase in TTC-specific IgG titres in calves
This is the first time the magnitude and the kinetics of the T-D and T-I2 antigen specific B cell response has been described in cattle. Briefly, the response to the T-D antigen was characterised by an expansion of TNP-specific plasma cells peaking at day 7 post-TNP primary immunisation, which was associated with a subsequent increase in the titre of TNP-specific IgG antibodies. Following booster immunisation, a larger TNP-specific plasma cell burst was detected at day 3 to 5 post-TNP boost, and was similarly associated with a larger increase in TNP-specific IgG titres. The timing and magnitude of the T-D antigen-specific plasma cell bursts is in agreement with the findings of a previously published study, in which calves were immunised with another T-D model antigen, ovalbumin. Moreover, a plasma cell burst has also been previously detected (with identical kinetics: 6 to 7 days post-primary immunisation) in humans following their immunisation with a number of different antigens, such as inactivated influenza virus, respiratory syncytial virus, serogroup C meningococcal polysaccharides and tetanus toxoid. The timing and magnitude of the secondary plasma cell burst and increased IgG response, i.e. a rapid and larger secondary response, is in keeping with the central dogma of immunological priming by a T-D antigen[15, 22].
There was an increase in the number of TNP-specific memory B cells from day 3 post-TNP-CGG boost that peaked at day 6 to 7 post-TNP boost. TNP-specific and CGG-specific memory B cells were still detectable in the blood of calves from the T-D group at day 34 post-TNP boost. The timing and magnitude of this T-D antigen specific response, following booster immunisation, is in keeping with other previously published data. Although no TNP-specific memory B cells were detected in the T-D group following the primary immunisation. Previous studies in both humans and cattle have shown low numbers of antigen-specific memory B cells following primary immunisation with a T-D antigen[4, 15]. The rapid induction of TNP-specific plasma cells from day 3 post-TNP boost and the associated increase in TNP-specific IgG antibody titres observed in the T-D group suggests that a number of TNP-specific memory B cells were indeed generated after primary immunisation, but the quantities in blood were below the detection levels of our ELISPOT assay.
T-independent antigens are unable to prime individuals for a secondary immune response. In this study the T-I2 group showed no detectable TNP-specific plasma or memory B cells, after either the primary or booster immunisation with TNP-AECM-FICOLL. Despite the lack of detectable antigen-specific plasma or memory B cells in the blood, there was a small increase in TNP-specific IgG titres in this group following primary and booster immunisations. It is likely that this increase in antibody titres results from the in situ generation of short-lived plasma cells, as previously described. These findings are in keeping with Fink et al. who suggest that the absence of specific T cell help results in reduced germinal centre formation, which promotes an extra follicular plasma cell response, favouring short-lived plasma cell formation. Kelly et al. have also shown that following primary immunisation with a T-I2 antigen, serogroup C meningococcal capsular polysaccharide, very low/undetectable numbers of antigen-specific memory B cells were generated. The results from the present study shows that in cattle the kinetics and magnitude of the T-I2 antigen-specific plasma and memory B cell response is similar to that of the human and mouse.
Immunisation with the third party antigen (TTC) in this study resulted in similar TTC-specific plasma and memory B cell kinetics that have been previously described for other TD antigens[4, 15, 20, 21]. Briefly, a burst of TTC-specific plasma cells was detected from day 7 to 14 post-TTC primary immunisation and from day 3 to 5 post-TTC boost in all animals. Interestingly, we found that the TTC-specific plasma cell bursts in the T-D group were also associated with a small increase in the number of TNP- and CGG-specific plasma cells post-TTC primary immunisation and/or boost. These results are consistent with those previously published by Bernasconi et al., which demonstrated a bystander polyclonal differentiation of memory B cells into plasma cells specific for various recall antigens (Toxoplasma gondii and measles virus) following the immunisation of humans with an unrelated T-D antigen (tetanus toxoid).
There was a steady increase in the number of TTC-specific memory B cells post-TTC primary immunisation followed by at least a 14 fold increase in the number of these cells post-TTC boost. The T-D group also showed an increase in the number of TNP- and CGG-specific memory B cells only post-TTC boost (at day 6–8 post-TTC boost). Based on the timing of emergence of the TNP- and CGG memory B cells, it is unlikely that these memory B cells were generated from newly activated naïve B cells, but instead suggests that pre-existing TNP- and CGG-specific memory B cells were subjected to one (or more) round(s) of antigen-independent (bystander) proliferation within the T-cell regions of the draining lymph node. This bystander stimulation of T-D antigen-specific plasma and memory B cells may provide a mechanism for maintaining long term T-D antigen-specific antibody titres.
In conclusion, the present study showed that bystander stimulation of an established T-D B cell memory response may occur in cattle, providing a possible mechanism of maintaining protective antibody titres for long periods of time. Our findings also provided a better characterisation of the key differences between T-D and T-I immune responses in cattle. However, as highlighted by Fink et al., more studies are required to further elucidate the mechanisms of the T-D and T-I2 activation of antigen-specific plasma cells. As demonstrated by this study and others[4, 15, 22], clearly the timing and magnitude of the antigen-specific plasma cell response is dependent on a number of factors, including the nature of the immunising antigen.
This knowledge will be particularly useful in elucidating the B cell response to the largely T-I antigen, FMDV. Indeed as mentioned previously, most natural pathogens contain both T-I and T-D antigens, but viruses such as FMDV tend to preferentially generate a T-I immunological response. FMDV is a highly contagious virus infecting cloven-hoofed animals, leading to skin erosions of the cutaneous mucosa. The virus has a significant global socio-economic impact, and the maintenance of FMDV-free status is critical for the free trade of animals and animal products. One of the main methods of FMDV disease control and eradication is through vaccination. The current FMDV vaccine only promotes short-term humoral immunity (presumably due to the essentially T-I nature of this virus), and regular repeat vaccinations are used to maintain protective IgG antibody titres, due to the lack of long-term immunological protection. Therefore, future studies including a more detailed assessment of the B cell response against FMDV in cattle could provide important data to underpin a better evaluation of novel candidate vaccines that induces a robust and sustained T-D rather than a T-I response.
Antibody secreting cell
The authors would like to thank the International Livestock Research Institute (ILRI, Kenya) for providing the ILA158 mAb, Dr Gary Entrican (Moredun Research Institute, UK) for providing the recombinant bovine IL-10 and the animal technicians at the Institute for Animal Health (IAH, UK) for the care of the animals. Financial support for this research was given by Merial Animal Health and the Biotechnology and Biological Sciences Research Council (Grant number: BBS/E/I/00001464). AJP and BC are Jenner Institute Investigators and AJP is a James Martin Senior Fellow.
- Hangartner L, Zinkernagel RM, Hengartner H: Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006, 6: 231-243. 10.1038/nri1783.View ArticlePubMedGoogle Scholar
- Ndungu FM, Cadman ET, Coulcher J, Nduati E, Couper E, Macdonald DW, Ng D, Langhorne J: Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog. 2009, 5: e1000690-10.1371/journal.ppat.1000690.PubMed CentralView ArticlePubMedGoogle Scholar
- Mond JJ, Vos Q, Lees A, Snapper CM: T cell independent antigens. Curr Opin Immunol. 1995, 7: 349-354. 10.1016/0952-7915(95)80109-X.View ArticlePubMedGoogle Scholar
- Lefevre EA, Carr BV, Prentice H, Charleston B: A quantitative assessment of primary and secondary immune responses in cattle using a B cell ELISPOT assay. Vet Res. 2009, 40: 3-10.1051/vetres:2008041.View ArticlePubMedGoogle Scholar
- McHeyzer-Williams MG: B cells as effectors. Curr Opin Immunol. 2003, 15: 354-361. 10.1016/S0952-7915(03)00046-3.View ArticlePubMedGoogle Scholar
- Eisen HN, Siskind GW: Variations in affinities of antibodies during the immune response. Biochemistry. 1964, 3: 996-1008. 10.1021/bi00895a027.View ArticlePubMedGoogle Scholar
- Griffiths GM, Berek C, Kaartinen M, Milstein C: Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature. 1984, 312: 271-275. 10.1038/312271a0.View ArticlePubMedGoogle Scholar
- Manz RA, Thiel A, Radbruch A: Lifetime of plasma cells in the bone marrow. Nature. 1997, 388: 133-134. 10.1038/40540.View ArticlePubMedGoogle Scholar
- Slifka MK, Antia R, Whitmire JK, Ahmed R: Humoral immunity due to long-lived plasma cells. Immunity. 1998, 8: 363-372. 10.1016/S1074-7613(00)80541-5.View ArticlePubMedGoogle Scholar
- Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002, 298: 2199-2202. 10.1126/science.1076071.View ArticlePubMedGoogle Scholar
- Feldmann M, Easten A: The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med. 1971, 134: 103-119. 10.1084/jem.134.1.103.PubMed CentralView ArticlePubMedGoogle Scholar
- Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ: B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000, 176: 154-170.View ArticlePubMedGoogle Scholar
- Mond JJ, Lees A, Snapper CM: T cell-independent antigens type 2. Annu Rev Immunol. 1995, 13: 655-692. 10.1146/annurev.iy.13.040195.003255.View ArticlePubMedGoogle Scholar
- Adderson EE: Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations. Springer Semin Immunopathol. 2001, 23: 387-403. 10.1007/s281-001-8166-x.View ArticlePubMedGoogle Scholar
- Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ: CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. 2006, 108: 2642-2647. 10.1182/blood-2006-01-009282.View ArticlePubMedGoogle Scholar
- Pollard AJ, Perrett KP, Beverley PC: Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009, 9: 213-220. 10.1038/nri2494.View ArticlePubMedGoogle Scholar
- Juleff N, Windsor M, Lefevre EA, Gubbins S, Hamblin P, Reid E, McLaughlin K, Beverley PC, Morrison IW, Charleston B: Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naive cattle. J Virol. 2009, 83: 3626-3636. 10.1128/JVI.02613-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Zinkernagel RM, Hengartner H: Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev. 2006, 211: 310-319. 10.1111/j.0105-2896.2006.00402.x.View ArticlePubMedGoogle Scholar
- Brodeur SR, Angelini F, Bacharier LB, Blom AM, Mizoguchi E, Fujiwara H, Plebani A, Notarangelo LD, Dahlback B, Tsitsikov E, Geha RS: C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity. 2003, 18: 837-848. 10.1016/S1074-7613(03)00149-3.View ArticlePubMedGoogle Scholar
- Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, Treanor J, Feng C, Sanz I, Lee FE: Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine. 2010, 28: 3582-3587. 10.1016/j.vaccine.2010.02.088.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee FE, Falsey AR, Halliley JL, Sanz I, Walsh EE: Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis. 2010, 202: 1659-1666. 10.1086/657158.View ArticlePubMedGoogle Scholar
- Fink K, Manjarrez-Orduno N, Schildknecht A, Weber J, Senn BM, Zinkernagel RM, Hengartner H: B cell activation state-governed formation of germinal centers following viral infection. J Immunol. 2007, 179: 5877-5885.View ArticlePubMedGoogle Scholar
- Belsham GJ, Charleston B, Jackson T, Paton DJ: Foot-and-Mouth Disease. eLS. 2009, John Wiley & Sons, Ltd,http://dx.doi.org/10.1002/9780470015902.a0001024.pub2,Google Scholar
- Brehm KE, Kumar N, Thulke HH, Haas B: High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine. 2008, 26: 1681-1687. 10.1016/j.vaccine.2008.01.038.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.